Industry Insights

World BioHazTec has been a leader in biosafety and biosecurity since its inception in 1995. Over the years, we have successfully completed numerous groundbreaking projects and received prestigious awards, showcasing our dedication to excellence and innovation.

background decorative image
A lab worker working in a lab

Why Independent Certification Strengthens Biosafety Programs

Across the world, many laboratories rely on in-house certification programs often supported by building management systems (BMS) and internal maintenance teams to meet annual compliance requirements. While these approaches can satisfy baseline regulatory expectations, they may not always deliver the level of assurance needed in today’s increasingly complex biosafety environment. As laboratories evolve to support advanced research, biomanufacturing, and high-consequence pathogen work, there is a growing case for incorporating independent, third-party certification into routine practice. The Limitations of In-House Certification In-house certification programs offer convenience and cost control, but they also present inherent limitations: Potential bias and conflict of interest Internal teams are often responsible for both maintaining and verifying system performance. This can unintentionally create blind spots or reduce critical scrutiny. Overreliance on Building Management Systems BMS platforms are valuable tools but they are not designed to provide comprehensive certification. They typically monitor trends rather than validate performance under test conditions. A system may appear stable in the BMS, yet fail to meet containment or airflow requirements when independently tested. Limited diagnostic depth Internal checks often confirm that equipment is “functioning,” but may not assess whether it is operating optimally, especially under stress, failure scenarios, or edge conditions. Why Third-Party Certification Matters Engaging an independent certifier introduces a higher level of rigor, objectivity, and technical depth. True Independence and Objectivity Effective biosafety depends on the interaction of facility systems, administrative controls, maintenance practices, and laboratory operations. Independent reviewers evaluate these elements as an integrated system rather than assessing individual components in isolation. A third-party certifier has no stake in the facility’s operations, maintenance contracts, or internal performance metrics. This independence ensures: Unbiased evaluation Transparent reporting Identification of issues that internal teams may overlook This is especially critical in environments where safety margins are thin and consequences are high. Verification Beyond the BMS While a BMS provides continuous monitoring, certification requires active testing. Third-party certification includes: Direct measurement using calibrated, independent instrumentation Verification of airflow, pressure differentials, and containment performance Challenge testing to confirm system integrity under real-world conditions This approach moves beyond “data observation” and into performance validation. Engineering-Level Interpretation Data alone does not equal insight. Third-party certification brings: Engineering interpretation of results Contextual understanding of system design and intent Identification of systemic issues rather than isolated failures Third-party reviewers evaluate not only whether systems meet current performance criteria, but also whether they continue to operate in accordance with the facility's original design intent. For example: A pressure cascade may meet minimum thresholds, but fluctuate in a way that compromises containment Air change rates may appear compliant but fail to support effective contaminant dilution These nuances are often only recognized when data is interpreted by experienced biocontainment engineers. Independent Review of Administrative Controls Engineering controls are only one component of an effective biosafety program. Administrative procedures—including risk assessments, standard operating procedures, training programs, incident response processes, and documentation systems—play an equally important role in maintaining safety and compliance. An external reviewer brings a fresh, objective perspective that internal personnel may not be able to provide. Over time, organizations can become accustomed to long-standing practices and assumptions, making it difficult to identify procedural gaps, inefficiencies, or areas where written policies no longer reflect actual laboratory operations. Laboratories also evolve over time through personnel turnover, equipment upgrades, procedural revisions, and changing research activities. Periodic independent reviews help ensure that administrative controls continue to align with current operations and biosafety risks. A third-party review can: Evaluate whether administrative controls align with current biosafety risks Identify gaps between documented procedures and day-to-day practices Assess the effectiveness of training and competency programs Review documentation, recordkeeping, and corrective action processes Provide benchmarking against industry best practices and peer facilities This independent perspective often uncovers opportunities for improvement that may be overlooked during routine internal reviews, helping laboratories strengthen both their biosafety culture and overall operational effectiveness. Alignment with Evolving Global Expectations Across the world, regulatory frameworks emphasize risk management, traceability, and demonstrable control but often allow flexibility in how certification is achieved. By incorporating third-party certification, laboratories can: Strengthen compliance posture beyond minimum requirements Demonstrate due diligence to regulators and stakeholders Align with international best practices This is particularly relevant for facilities engaged in: Cross-border collaborations Pharmaceutical manufacturing High-containment (BSL-3/4) operations Raising the Standard, Not Just Meeting It In-house certification frequently focuses on confirming that systems meet predefined limits. Third-party certification, by contrast, asks a deeper question: Is the system performing at the level required to ensure safety and reliability? This shift in perspective leads to: Early identification of degradation trends Validation of corrective actions and continuous improvement initiatives Improved system resilience Enhanced protection for personnel, products, and the environment Effective biosafety depends on the interaction of engineering controls, administrative procedures, maintenance programs, and laboratory practices. Independent certification evaluates these elements as an integrated system rather than as isolated components. A Complementary Approach It’s important to note that third-party certification is not a replacement for internal programs—it is a critical complement. The most effective laboratories combine: Continuous monitoring via BMS Routine internal operational and administrative reviews Periodic independent certification of engineering controls and administrative programs This layered approach provides both operational continuity and objective validation. Conclusion As the global bioscience landscape continues to advance, so too must the standards that underpin laboratory safety and performance. Relying solely on in-house certification and building management systems may no longer be sufficient to meet the demands of modern research and production environments. By incorporating third-party certification, laboratories gain not only compliance assurance—but a deeper understanding of how their facilities, administrative controls, and laboratory practices work together to support biosafety. Ultimately, independent certification is not just about checking a box—it’s about achieving a higher standard of biosafety. Ready to have your lab certified? Contact us for a free consultation.

Read More
A large meeting taking place in a boardroom

Why Biosafety Is Becoming a Boardroom Issue

For decades, biosafety lived primarily within the walls of the laboratory—managed by safety officers, addressed during audits, and often viewed as a compliance requirement rather than a strategic priority. That paradigm is shifting. As biological research accelerates and the consequences of incidents, including near misses, grow more visible, biosafety has moved beyond a technical discipline and into the realm of enterprise risk. Incidents now carry implications for operations, funding, governance, and reputation, making biosafety not just a laboratory concern, but a defining issue for leadership and the boardroom. Today, biosafety is no longer just a technical function; it is increasingly a boardroom issue, driven by growing risk exposure, investor expectations, grant funding requirements tied to biosafety and biosecurity oversight, and the global implications of biological research. Organizations that fail to recognize this shift risk more than failed inspections; they are vulnerable to operational disruption, funding challenges, regulatory exposure, and erosion of stakeholder trust. Risk Exposure Has Moved Up the Chain Modern bioscience operates at unprecedented speed and complexity. Advanced therapeutics, synthetic biology, and global collaboration have expanded both opportunity and risk, making biosafety incidents more visible and more consequential. When biosafety programs are underdeveloped or poorly integrated, the impacts quickly extend beyond technical operations and into enterprise performance. A single biosafety incident can trigger operational shutdowns; regulatory scrutiny; loss of funding; legal liability; and risks to employee and public safety. These are not isolated technical issues; they are enterprise risks that affect continuity, reputation, and long-term viability. As a result, executives and boards are increasingly accountable to ensure that biosafety is not just present, but effective. Research confirms that laboratory incidents are not rare and are rarely purely technical failures. A systematic review of laboratory-acquired infections identified hundreds of documented cases, many linked to procedural lapses, ineffective containment practices, and improper handling of biological materials (Dhawan et al., 2025). Similarly, broader policy analysis of global laboratory accidents shows that such incidents continue to occur regularly, with the majority attributed to avoidable human error and inadequate procedures, even in regulated environments (Ross & Harper, 2023). Large-scale longitudinal analysis further reinforces this pattern. A study of 1,126 laboratory-associated incidents spanning 1900–2025 found that outbreaks and severe outcomes were most strongly linked to operational failures, including improper inactivation, aerosol leaks, and poor decontamination practices (Dhawan et al., 2026).  These findings underscore a critical point: biosafety risk is systemic. It is shaped by how programs are designed, funded, and executed; not simply whether required procedures exist. A clear example occurred in 2025 at the Integrated Research Facility at Fort Detrick, a high-containment laboratory capable of Biosafety Level 4 (BSL‑4) research on high-consequence pathogens (National Institute of Allergy and Infectious Diseases [NIAID], 2026). Operations were halted following a serious biosafety incident involving personnel misconduct, after a contractor damaged a colleague’s protective suit, potentially exposing them to dangerous pathogens and triggering federal investigation (Minnaugh, 2025). The event exposed vulnerabilities in safety culture and governance, demonstrating how quickly even highly controlled environments can escalate into enterprise risk. Forward-looking organizations are reframing biosafety as part of their enterprise risk architecture, alongside cybersecurity, financial controls, and operational resilience. The question is no longer “Are we compliant?” but “Are we protected?” Investors Are Expanding the Definition of Risk Investor scrutiny is another major force elevating biosafety to the executive level. Across the life sciences sector, due diligence has expanded beyond scientific validity and market opportunity to include regulatory readiness, operational resilience, and governance effectiveness, reflecting a broader understanding of risk. Increasingly, biosafety and biosecurity risks are being captured within broader assessments of operational, regulatory, and governance risk. While investors may not evaluate biosafety as a standalone category, they are increasingly sensitive to the types of failures—safety incidents, compliance gaps, and governance breakdowns—that biosafety programs are designed to mitigate. This shift is reinforced by the growing role of ESG—environmental, social, and governance—factors in investment decisions. ESG frameworks are widely used to evaluate how organizations manage risk and accountability beyond financial performance, incorporating considerations such as safety practices, governance quality, and operational transparency (CFA Institute, 2024).  Institutional investor research shows that ESG is now widely used as a risk assessment lens, with strong emphasis placed on governance, transparency, and accountability as indicators of organizational resilience and oversight (CFA Institute, 2024; EY, 2024). Investors are also demanding greater transparency, with organizations facing mounting pressure to provide reliable, decision-useful disclosures related to governance and risk management (EY, 2024; Miranda Partners, 2024). This growing emphasis on transparency and accountability reflects concerns about credibility and risk visibility, leading investors to place greater weight on demonstrated systems and governance maturity (Foley, 2025). The result is a clear shift: while biosafety may not be evaluated explicitly, it increasingly influences how investors assess organizational maturity, scalability, and risk exposure. Organizations with strong, integrated biosafety systems signal discipline, operational control, and readiness for growth—qualities that attract confidence and investment interest. Conversely, gaps in biosafety can raise concerns about governance, execution, and risk management, potentially limiting investor confidence and slowing funding or partnership opportunities. This perspective is not limited to investors. It reflects a broader shift in how biosafety is being evaluated across regulatory, governmental, and global health frameworks. Global Health Implications Are Reshaping Expectations This perspective is not limited to investors. It reflects a broader shift in how biosafety is being evaluated across regulatory, governmental, and global health frameworks. The global environment has fundamentally changed how biosafety is perceived. In response to COVID‑19 and emerging disease threats, governments and international organizations are expanding biosafety into formal policy, regulation, and global governance frameworks. International efforts such as updates to the International Health Regulations and the development of a Pandemic Agreement reflect increasing expectations for coordination, transparency, and preparedness at a global scale (WHO, 2024; WHO, 2025). These initiatives signal a move toward structured accountability, where both nations and organizations are expected to demonstrate effective biosafety systems. At the same time, standardized approaches are gaining traction across sectors. ISO 35001, the international standard for biorisk management, is increasingly recognized as a framework for systematically identifying, assessing, and managing biological risk (ISO, 2019). Unlike traditional compliance-driven approaches, ISO 35001 positions biosafety as an integrated management system aligned with governance, operations, and organizational culture, supporting consistency, auditability, and continuous improvement. National initiatives reinforce this trend. Programs such as the NIH Biosafety Modernization Initiative reflect the need to adapt oversight systems to rapidly advancing biotechnology (NIH, 2025). At the same time, global investment in pandemic preparedness, including laboratory infrastructure and surveillance systems, continues to expand through multilateral initiatives such as the Pandemic Fund, which supports capacity building across more than 100 countries, reinforcing that biological risk is shared and systemic (Pandemic Fund, 2026). Together, these developments make clear that biosafety is no longer an internal operational concern. It is part of a global system of accountability, coordination, and risk management, where organizations are expected to demonstrate not just compliance, but capability, consistency, and control. From Compliance to Strategic Integration Despite this shift, many organizations still approach biosafety as a checklist exercise. Policies are written, training is conducted, and audits are passed; however, gaps persist because the program is not fully integrated into how the organization operates. Evidence consistently shows that biosafety incidents are not driven by missing requirements, but by breakdowns in execution, culture, and system design. Research reinforces this point. Reviews of laboratory-acquired infections and biosafety incidents demonstrate that many events are linked to procedural lapses, inadequate training, and failures in implementation, rather than the absence of formal controls (Ross & Harper, 2023). These findings highlight a critical reality: biosafety performance depends on how systems function in practice, not simply how they are documented. Leading frameworks are evolving accordingly. The World Health Organization emphasizes a risk-based, integrated approach that connects technical controls with training, procedures, and governance structures, recognizing that effective biosafety requires coordination across the entire organization (WHO, 2020). Similarly, ISO 35001 formalizes biosafety as a biorisk management system, requiring organizations to embed risk identification, mitigation, and performance monitoring into everyday operations rather than isolated compliance activities (ISO, 2019). In practice, this means biosafety must be integrated into facility design and infrastructure; operational processes; governance structures; organizational culture; and budgeting and resource allocation, ensuring programs are sustainably funded and aligned with growth and risk exposure. At the board level, budgeting decisions ultimately determine whether biosafety is treated as a compliance obligation or a fully integrated risk management system. Organizations that adopt this approach move beyond reactive correction and toward measurable performance. They align biosafety with how work is performed, creating systems that are resilient, scalable, and continuously improving. The distinction is clear: compliance ensures requirements are met; integration ensures biosafety actually works. The Bottom Line Biosafety is no longer confined to the laboratory. It is a defining component of organizational integrity, risk management, and long-term performance. As incident visibility increases, investor expectations evolve, and global accountability frameworks expand, biosafety has moved firmly into the realm of executive oversight. Organizations that continue to treat biosafety as a technical afterthought will face increasing exposure to operational disruption, regulatory action, and reputational risk. By contrast, those that integrate biosafety into strategy, governance, and culture position themselves to manage risk proactively, scale responsibly, and maintain confidence among investors, regulators, and partners. The distinction is no longer between compliant and noncompliant organizations—it is between those that have integrated biosafety into how they operate and those that have not. The question is no longer whether biosafety belongs in the boardroom. The real challenge is whether your organization is prepared to lead with it. A Different Approach to Biosafety At World BioHazTec, we don’t approach biosafety as a checklist, or as a theoretical exercise disconnected from operational reality. Our work is grounded in the direct evaluation of more than 300 laboratory programs, providing a clear understanding of where systems break down and why even capable organizations struggle to meet certification and performance expectations. We partner with organizations to design and implement fully integrated biosafety systems, aligned with facility design, operational workflows, leadership oversight, and long-term growth. This ensures biosafety is embedded into how work is performed, rather than layered on after the fact. Our focus is not just on compliance, but on system performance and how biosafety functions in practice, under pressure, and over time. In today’s environment, the presence of a program is not enough; its effectiveness determines the level of risk. Biosafety is not just about passing an inspection. It is about protecting your people, your science, and your organization, while demonstrating the discipline, governance, and resilience expected by regulators, investors, and global stakeholders. If biosafety has reached your boardroom, it’s time to manage it as a strategic system. Works Cited CFA Institute. (2024). What is ESG investing? https://www.cfainstitute.org/insights/articles/what-is-esg-investing Dhawan, S., Lim, P. L., Pan-ngum, W., MacIntyre, C. R., & Blacksell, S. D. (2025). Determinants of fatalities and secondary transmission in laboratory pathogen incidents, 1900–2025. The Lancet Microbe. https://doi.org/10.1016/S2666-5247(25)00085-0 Dhawan S, Muluneh A, Pan-gnum W et al. Risk factors and mitigation strategies of laboratory-acquired infections in research and clinical laboratories worldwide: a systematic review. The Lancet Microbe, 2025; 6 (2024). Global Institutional Investor Survey. Foley, M. (2025). How investors are driving ESG transparency. Forbes. International Organization for Standardization (ISO). (2019). ISO 35001:2019 Biorisk management for laboratories and related organizations. https://www.iso.org/standard/71293.html National Institute of Allergy and Infectious Diseases (NIAID). (2026). Integrated Research Facility at Fort Detrick. https://www.niaid.nih.gov/research/frederick-integrated-research-facility Minnaugh, R. (2025). FBI investigates Fort Detrick lab incident as fight leads to potential pathogen exposure. https://thenationaldesk.com/news/americas-news-now/fbi-investigates-fort-detrick-lab-incident-as-fight-leads-to-potential-pathogen-exposure Miranda Partners. (2024). Highlights from global corporate reporting survey. Pandemic Fund. (2026). Strengthening pandemic prevention, preparedness, and response. https://www.thepandemicfund.org/ Ross, A., & Harper, K. (2023). Global biosecurity and laboratory safety risks. Chatham House. Stanford Graduate School of Business, Hoover Institution, & MSCI. (2024). Institutional Investor Survey on Sustainability. World Health Organization (WHO). (2020). Laboratory Biosafety Manual (4th ed.). https://www.who.int World Health Organization (WHO). (2024). International Health Regulations (amendments). https://www.who.int World Health Organization (WHO). (2025). Pandemic Agreement. https://www.who.int

Read More
A laptop sitting on the floor next to a BSL-3 lab door

Why Cracking the Door Gets BSL-3 Airflow Wrong

What the BMBL, NIH DRM, and ANSI/ASSP Standards Actually Say About Directional Airflow Questions about directional airflow in BSL‑3 laboratories sometimes arise during government oversight, particularly when qualitative techniques such as smoke visualization are used. To evaluate these situations correctly, observations must align with established biosafety guidance and recognized engineering standards, rather than informal or non‑representative test conditions (BMBL, 6th ed.; NIH DRM; ANSI/ASSP Z9.14). Taken together, the Biosafety in Microbiological and Biomedical Laboratories (BMBL), the NIH Design Requirements Manual (DRM), and ANSI/ASSP laboratory ventilation standards all emphasize the same foundational principle: directional airflow is an engineered pressure condition that must be verified quantitatively and under normal operating conditions (BMBL, 6th ed.; NIH DRM §6.6; ANSI/ASSP Z9.14). Directional Airflow Is a Pressure‑Control Function The BMBL defines directional airflow in terms of pressure differentials, requiring BSL‑3 laboratories to be maintained at negative pressure relative to adjoining spaces so that airflow moves inward toward areas of higher risk (BMBL, 6th ed.). The NIH Design Requirements Manual reinforces this requirement by translating biosafety goals into enforceable engineering criteria. The DRM specifies that BSL‑3 laboratories must incorporate pressure cascades, continuous differential pressure monitoring, and alarmed systems to confirm airflow direction on an ongoing basis (NIH DRM §6.6, Mechanical Systems). Both documents treat directional airflow as a measurable HVAC performance parameter, not something inferred from short‑term visual observations (BMBL, 6th ed.; NIH DRM). Why Standards‑Based Engineering Rejects the “Cracked Door” Test ANSI/ASSP laboratory ventilation standards provide additional clarity regarding acceptable testing methods. ANSI/ASSP Z9.14 establishes that airflow performance must be evaluated using appropriate instruments and under representative operating conditions, particularly in laboratories designed with pressure control systems (ANSI/ASSP Z9.14). When calibrated pressure instrumentation is present, Z9.14 identifies differential pressure measurement as the primary indicator of directional airflow and cautions against drawing conclusions from conditions that defeat the designed airflow regime (ANSI/ASSP Z9.14). Cracking a door during testing introduces a large, uncontrolled opening that collapses the pressure differential, creates turbulence, and invalidates the engineered pressure cascade—conditions explicitly inconsistent with how laboratory ventilation systems are designed to be assessed (ANSI/ASSP Z9.14; NIH DRM §6.6). BSL‑3 Laboratories Are Leaky by Design Across biosafety guidance and engineering standards, there is a shared recognition that BSL‑3 laboratories are not airtight. The BMBL describes containment as a function of primary and secondary barriers working together to minimize release, not as the elimination of all leakage (BMBL, 6th ed.). Doors, frames, and penetrations are expected to have small leak paths, which are accounted for in design. The NIH DRM similarly assumes leakage and relies on negative pressure maintenance to ensure that air moves inward through these paths rather than outward (NIH DRM §6.6). ANSI/ASSP standards align with this approach, emphasizing pressure relationships as the controlling mechanism for airflow direction (ANSI/ASSP Z9.14). Containment is therefore achieved through controlled inward airflow, not by seal tightness. Normal Operating Conditions Matter BSL‑3 laboratory doors are required to be self‑closing and self‑latching, ensuring that performance is evaluated with doors either fully closed and latched or fully open briefly during passage (BMBL, 6th ed.). Neither the BMBL nor the NIH DRM recognizes a partially open, held door as a valid operating condition for assessing containment performance (BMBL, 6th ed.; NIH DRM §6.6). ANSI/ASSP Z9.14 similarly emphasizes that testing must reflect how the space is designed to operate, not artificial configurations introduced for convenience (ANSI/ASSP Z9.14). Airflow behavior observed under non‑representative conditions cannot be reliably correlated to system performance. Unified Message Across All Standards Viewed together, the guidance is unequivocal: The BMBL defines the biosafety objective: inward directional airflow achieved through negative pressure (BMBL, 6th ed.). The NIH DRM defines how that objective is engineered, monitored, and verified (NIH DRM §6.6). ANSI/ASSP Z9.14 defines how airflow performance should be evaluated using accepted ventilation engineering practice (ANSI/ASSP Z9.14). None of these authorities support determining loss of containment based on smoke behavior observed during a cracked‑door test. Final Takeaway Directional airflow in BSL‑3 laboratories is an engineered pressure condition, not a visual effect. The BMBL, NIH Design Requirements Manual, and ANSI/ASSP laboratory ventilation standards all reinforce that quantitative pressure verification under normal operating conditions is the correct and defensible method for assessing airflow performance (BMBL, 6th ed.; NIH DRM §6.6; ANSI/ASSP Z9.14). Smoke visualization may serve as a supplemental diagnostic tool, but it cannot override calibrated pressure data or be used under conditions that undermine system design intent. Alignment with these standards supports clear, consistent, and technically defensible evaluations of containment performance. Works Cited American National Standards Institute (ANSI) / American Society of Safety Professionals (ASSP). ANSI/ASSP Z9.14-2020 – Testing and Performance-Verification Methodologies for Biosafety Level 3 (BSL-3) and Animal Biosafety Level 3 (ABSL-3) Ventilation Systems. Centers for Disease Control and Prevention (CDC) & National Institutes of Health (NIH). Biosafety in Microbiological and Biomedical Laboratories (BMBL), 6th Edition. U.S. Department of Health and Human Services, June 2020. Available at: https://www.cdc.gov/labs/bmbl/index.html National Institutes of Health (NIH), Office of Research Facilities (ORF). NIH Design Requirements Manual for Biomedical Laboratories and Animal Research Facilities (DRM). Current Edition, Sections 6.6 and 7 (Mechanical Systems; Biosafety Level‑3 Requirements). Available at: https://orf.od.nih.gov/TechnicalResources/Pages/Design-Requirements-Manual.aspx National Institutes of Health (NIH), Office of Research Facilities. BSL‑3 and ABSL‑3 HVAC System Requirements. NIH ORF Technical Guidance Documents and DRM Interpretive Publications.

Read More

Top Picks

IACET Accredited Provider logo

World BioHazTec is an Accredited Provider (AP) of the International Association for Continuing Education and Training (IACET). As an IACET Accredited Provider, World BioHazTec offers IACET CEUs for its learning events that comply with the ANSI/IACET Continuing Education and Training Information.

Level Up

Ready to Practice Safe Science?

Let's Get Started